Global Dermatitis Herpetiformis Treatment Market is segmented By Treatment (Dietary (gluten-free diet), Therapeutics, By Route of Administration, Topical, Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Market Overview
The "Global Dermatitis Herpetiformis Treatment Market" is predicted to reach at a high CAGR of 6.50% during the forecast period (2023-2030)
Dermatitis herpetiformis, a chronic and uncommon disease that resembles herpes, is caused due to the accumulation of immunoglobulin A in the skin, which produces reactions and leads to lesion formation. The disease causes intense itchiness and blistering of the skin and is more common in men. Dermatitis herpetiformis causes rashes and blisters in clusters on knees, buttocks, elbows, scalp, and back.
Source: DataM Intelligence Analysis (2021)
Market Dynamics
The dermatitis herpetiformis treatment market growth is driven by the shortage of gluten-free food in some countries, increasing incidence of dermatitis herpetiformis, rise in research & development of new treatment options, and surge in awareness.
Increasing incidence of dermatitis herpetiformis, is expected to drive the growth in the forecast period
The disease could affect patients aged between 15 and 40. The DermNet NZ organization has observed that males are more prone to the disease than females. Epidemiologically, DH is a rare disease, which affects mainly young adults. Although, it had been diagnosed in infants aged eight months and in older people aged ninety years. Males are more affected, with a ratio of 2:1, but in patients under 20, the ratio is 12 females for every eight males. Prevalence of DH varies across different countries, with 1:1,000,000 new cases per year in Germany, 11 per 100,000 in Scotland, 20-39 per 100,000 in Sweden and 58.8 per 100,000 in Ireland. Patients with dermatitis herpetiformis suffer from severe itchiness. This provides an opportunity for manufacturers to provide products that offer immediate relief.
Complications associated with dermatitis herpetiformis treatment is likely to hinder the market growth
However, patients may experience dental defects. Also, there are chances that dermatitis herpetiformis may be mistaken for scabies. Moreover, due to the intake of the treatment drugs, the patient suffers from anemia, osteoporosis, Type 1 diabetes, and thyroid disease.
COVID-19 Impact Analysis
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies' financial status in the urea cycle disorders treatment market. The private healthcare sector is one of the sectors, which the COVID-19 pandemic has majorly impacted. The pandemic has negatively impacted the global dermatitis herpetiformis market in various aspects such as research and development, production, and supply of medicines. The pandemic has also affected the growth of pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries.
Segment Analysis
The gluten-free diet segment is expected to hold largest share in this market segment
The gluten-free diet is the only recommended long-term treatment for dermatitis herpetiformis, and it also may help the patient avert internal damage related to gluten consumption. However, it's far from easy to eradicate dermatitis herpetiformis by following a gluten-free diet.
The topical segment is expected to hold largest share in this market segment
The first line of treatment for dermatitis herpetiformis is usually a topical prescription medication. These can come in various forms such as lotions, creams, suppositories and others. Such immediacy results in rapid acquisition and strong maintenance of behavior anticipated increasing the segment growth in the market.
The retail pharmacies segment is expected to hold largest share in this market segment
The retail Pharmacies segment is expected to dominate during the forecast period. Dermatitis herpetiformis medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost lipid-regulating drugs market growth.
Source: DataM Intelligence Analysis (2021)
Geographical Analysis
North America region holds the largest market share of global dermatitis herpetiformis treatment market
North America region is dominating the global dermatitis herpetiformis treatment market accounted for the largest market share. owing to the increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment for Dermatitis Herpetiformis. Moreover, hospitals and diagnostic centers in North America and Europe opt for new technologically advanced methods for the diagnosis of diseases such as dermatitis herpetiformis to enhance the treatment and efficacy of drugs.
Source: DataM Intelligence Analysis (2021)
Competitive Landscape
The global dermatitis herpetiformis treatment market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Allergan, Valeant Canada LP, GlaxoSmithKline plc, Nostrum Laboratories Inc, Pfizer Inc, HBC Chem, Shingles Skincare, Anvia Chemicals, Ivy Fine Chemicals and Aidance Scientific. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Dermatitis Herpetiformis Treatment Market Key Companies to Watch
GlaxoSmithKline
Overview: GlaxoSmithKline plc is a British multinational pharmaceutical company headquartered in Brentford, UK. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. The business segments include Pharmaceuticals, Vaccines and Consumer healthcare. GSK is extending 50 years of leadership in respiratory medicine with continued innovation in the development of treatments for asthma, chronic obstructive pulmonary disease (COPD), and other debilitating respiratory conditions. It operates its business in over 115 countries worldwide.
Product Portfolio: The Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology.
Why Purchase the Report?
- Visualize the composition of the dermatitis herpetiformis treatment market segmentation by treatment, route of administration, distribution channel, and region highlighting the key commercial assets and players.
- Identify commercial opportunities dermatitis herpetiformis treatment market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of dermatitis herpetiformis treatment market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global dermatitis herpetiformis treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
